# First In Human Safety, Pharmacokinetics and Anti-tumoral Activity of GM102 in Gynecological Cancers

> **NCT02978755** · PHASE1 · COMPLETED · sponsor: **GamaMabs Pharma** · enrollment: 78 (actual)

## Conditions studied

- Neoplasm, Gynecologic

## Interventions

- **DRUG:** GM102
- **DRUG:** GM102 escalating doses
- **DRUG:** GM102

## Key facts

- **NCT ID:** NCT02978755
- **Lead sponsor:** GamaMabs Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06
- **Primary completion:** 2020-06-10
- **Final completion:** 2020-06-10
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2022-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02978755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02978755, "First In Human Safety, Pharmacokinetics and Anti-tumoral Activity of GM102 in Gynecological Cancers". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT02978755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*